Skip to main content

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/predigen-logo.png

Predigen Can Accurately Predict Respiratory Viral Infection

Study Reveals Blood-Based Host Response Test Can Accurately Predict Respiratory Viral Infection in Pre-Symptomatic Patients Predigen Developing Diagnostic Tools Designed to Help Physicians Differentiate Bacterial from Viral Infections and Detect Acute Respiratory Illness Early  …

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/woman-massaging-her-foot-during-sport-practice-P3DZ7ZK.jpg

Newly published data shows positive results in KRYSTEXXA trial

MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate — Data adds to growing body of evidence on immunomodulation with KRYSTEXXA and emerging…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/aerie.jpg

Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

September 08, 2020 07:30 AM Eastern Daylight Time DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/insoma-bio-image-1-1.jpeg

Duke startup inSoma Bio looking to raise $1M

by WRAL TechWire — September 4, 2020 . DURHAM — Biotech startup InSoma Bio has raised $50,000 in security, according to a filing with the US Securities and Exchange Commission. One investor contributed to the round, which kicked off on…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/splitters-1-1.jpg

Sophisticated Modeling Boosts Split Ventilators to Emergency FDA Review

Researchers at Duke University have engineered a workaround to make ventilators safer and more efficient when splitting them between patients. With a set of biocompatible 3D-printed parts to control the amount of air being pushed…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/vaccination-is-important-for-immunization-P7JTW65-1.jpg

Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies

Sept. 1, 2020 12:05 UTC Immunomic Therapeutics Announces Publication of Results from 3 ATTAC Studies of CMV-Specific Dendritic Cell Vaccines for the Treatment of GBM ~25-35 % survival over 5 years from diagnosis in vaccinated…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/Covid-Mono-1.jpg

Duke Institute Tapped to Test Monoclonal Antibody Preventative for COVID-19

DURHAM, N.C. — The Duke Human Vaccine Institute Pandemic Prevention Program (DHVI-P3) has received an additional $7.6 million in federal funding to manufacture and test in humans a neutralizing monoclonal antibody for the prevention of COVID-19. The…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/health-science-medical-life-science-1.jpg

Three NC life science execs crack PharmaVoice ‘most inspiring’ list

Leading life sciences magazine PharmaVoice has named three North Carolina executives to its list of the 100 most inspiring leaders in the pharmaceutical industry. Named to PharmaVoice 100 are PPD’s Karen Kaucic, M.D., the company’s chief…

Read More

https://dws-test-02.oit.duke.edu/wp-content/uploads/2022/08/precision_revised_logo_1_color.png

Public company Precision BioSciences, Inc. earns key designation for leukemia treatment

The Durham drugmaker has received fast-track designation from regulators for its leukemia drug, meaning approval of the treatment could roll through its pipeline faster. Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated…

Read More